Novo Nordisk won a preliminary injunction against Ceban Ziekenhuisfarmacie B.V. from the District Court of The Hague in a patent infringement case involving a compounded semaglutide nasal sprayThe Court found that Ceban infringed Novo Nordisk’s supplementary protection certificate (SPC) covering semaglutide and ordered Ceban to cease the infringing activities, remove product listings, disclose supply chain information, and reimburse Novo Nordisk’s legal costsNovo Nordisk’s approved semaglutide medicines are Wegovy®, Ozempic® and Rybelsus®. No nasal spray formulation of semaglutide is approved by any regulatory authority
Bagsværd, Denmark, 5 August 2026 — The District Court of The Hague has granted Novo Nordisk a preliminary injunction against Ceban Ziekenhuisfarmacie B.V., ordering the company to immediately stop selling a compounded semaglutide nasal spray that infringes Novo Nordisk’s intellectual property. The ruling protects patients from unapproved formulations of semaglutide and reinforces the regulatory framework that ensures medicines meet established standards for quality, safety and efficacy.
The court found that Ceban infringed Novo Nordisk’s supplementary protection certificate covering semaglutide. In addition to ordering Ceban to cease the infringing activities, the ruling requires the company to remove references to the product from relevant listings and websites, provide information regarding its commercial supply chain, and reimburse Novo Nordisk’s legal costs.
“Protecting patients means protecting the integrity of the medicines they rely on,” said John F. Kuckelman, Group General Counsel, Novo Nordisk. “This decision sends a clear message that intellectual property rights protecting pharmaceutical innovation will be enforced. We will continue to take decisive legal action against those who unlawfully exploit our innovations or market unapproved semaglutide products in ways that jeopardise patient safety and undermine the regulatory framework that protects patients.”
Protecting patients from unapproved semaglutide products
Compounded medicines are pharmacy-prepared formulations that are not reviewed or approved by regulatory authorities such as the European Medicines Agency (EMA) or the
